AMNEAL PHARMACEUTICALS LLC v. RECKITT BENCKISER PHARMACEUTICALS INC. et al
MEMORANDUM AND/OR OPINION ORDER THAT INDIVIOR'S MOTION TO DISMISS (DOC. NO. 10 IN 16-CV-563) IS GRANTED IN PART AND DENIED IN PART AS OUTLINED HEREIN. ALL CLAIMS AGAINST RECKITT BENCKISER PHARMACEUTICALS INC. AND INDIVIOR PLC ARE DISMISSED. AMNE AL MAY FILE AN AMENDED COMPLAINT TO ATTEMPT TO CURE THE DEFICIENCIES IN ITS LANHAM ACT CLAIM WITHIN THIRTY (30) DAYS OF THE DATE OF THIS ORDER. SIGNED BY HONORABLE MITCHELL S. GOLDBERG ON 1/4/2017. 1/4/2017 ENTERED AND COPIES MAILED AND E-MAILED TO LIAISON COUNSEL. (SEE PAPER # 312 IN 13-MD-2445) (ems)
IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA
IN RE: SUBOXONE (BUPRENORPHINE
HYDROCHLORIDE AND NALAXONE)
THIS DOCUMENT APPLIES TO:
Amneal Pharmaceuticals LLC v.
Indivior Inc. et al., 16-cv-563
MDL NO. 2445
AND NOW, this 4th day of January, 2017, upon consideration of “Indivior, Inc.’s Partial
Motion to Dismiss Amneal’s Complaint” (Doc. No. 10), the response, reply and sur-reply
thereto, following oral argument, and in accordance with accompanying Memorandum Opinion,
it is hereby ORDERED that Indivior’s motion to dismiss is GRANTED in part and DENIED in
part as follows:
Amneal’s standalone delay claim relating to the REMS/SSRS process is DISMISSED.
Amneal’s Lanham Act False Advertising claim (Count 3) is DISMISSED.
All claims against Reckitt Benckiser Pharmaceuticals Inc. and Indivior PLC are
Amneal may file an amended complaint to attempt to cure the deficiencies in its Lanham
Act claim within thirty (30) days of the date of this Order.
BY THE COURT:
/s/ Mitchell S. Goldberg
MITCHELL S. GOLDBERG, J.
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?